Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 4

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 373Neoplasms 323Neoplasm Metastasis 286Leukemia, Myeloid, Acute 277Breast Neoplasms 271Colorectal Neoplasms 238Melanoma 193Ovarian Neoplasms 191Recurrence 183Multiple Myeloma 178Prostatic Neoplasms 156Lung Neoplasms 156Pancreatic Neoplasms 152Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 146Glioblastoma 145Triple Negative Breast Neoplasms 119Myelodysplastic Syndromes 114Carcinoma, Renal Cell 111Stomach Neoplasms 110Glioma 108Brain Neoplasms 105Advanced Solid Tumors 104Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Lymphoma, Large B-Cell, Diffuse 101Lymphoma 100Lymphoma, B-Cell 97Carcinoma, Hepatocellular 95Endometrial Neoplasms 92Lymphoma, Follicular 91

Interventions

tremelimumab 1durvalumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Solid Malignancies × 1 year × Clear all
NCT06725381 2026-05-08

A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 1 Recruiting
138 enrolled

Solid Malignancies

NCT02537418 2026-03-27

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Canadian Cancer Trials Group

Phase 1 Active not recruiting
153 enrolled

Solid Malignancies

NCT05006794 2026-01-07

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

Gilead Sciences

Phase 1 Active not recruiting
145 enrolled

Solid Malignancies

NCT06933069 2025-09-11

Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors

Taizhou Mabtech Pharmaceutical Co.,Ltd

Phase 1 Recruiting
55 enrolled

Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡